Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Did Not Seek Plan B “Minority Opinion,” Crawford Tells Subcommittee

This article was originally published in The Tan Sheet

Executive Summary

FDA never asked for or received a memo from former Reproductive Health Drugs Advisory Committee member David Hager, MD, outlining a "minority opinion" on the possible Rx-to-OTC switch of Plan B, Commissioner Lester Crawford stated July 26

You may also be interested in...



House Approps Subcommittee Slaps FDA On The Wrist For Crawford Absence

The House Appropriations/Agriculture Subcommittee voted May 17 to withhold 5% of the funds for FDA's central offices until Acting Commissioner Lester Crawford testifies before the committee on the President's FY 2006 budget request

Crawford Nomination Woes Grow With Coburn Hold, Hager Letter

FDA Acting Commissioner Lester Crawford's bid for the permanent post has been cast further into doubt by a Republican joining the list of Senators threatening holds on his nomination

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel